Stay updated on ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA new revision entry v3.6.5 is added to the history, replacing v3.6.4, reflecting a software/UI update to the page.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe record history now includes a new revision entry (v3.6.4), indicating a page version update. This change affects only the page's metadata and does not modify the study data, conditions, or listings.SummaryDifference0.1%

- Check44 days agoChange DetectedA new revision entry v3.6.3 was added to the study record history, and the previous entry v3.6.2 was removed from the list.SummaryDifference0.1%

- Check51 days agoChange DetectedA new revision entry v3.6.2 was added to the study record history, and the previous revision v3.6.0 was removed.SummaryDifference0.1%

- Check65 days agoChange DetectedA new study version v3.6.0 was posted with a recruitment-status update indicating no longer looking for participants, and the previous version v3.5.5 was removed from the history.SummaryDifference0.4%

- Check73 days agoChange DetectedThe record history now shows the latest revision as v3.5.5, replacing the previous v3.5.4 entry in the changes list.SummaryDifference0.1%

Stay in the know with updates to ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.